Sofinnova Partners

What they fund

• Early-Stage Biopharma — Founding or lead investments in groundbreaking therapeutic technologies via the Sofinnova Capital Strategy.
• Early-Stage Medtech — Company building and launch support through the Sofinnova MD Start accelerator for early-stage medtech ventures.
• Growth-Stage Biotech — Investments in companies with clinically validated technologies preparing for commercialization via the Crossover Strategy.
• Digital Medicine Startups — Early-stage backing for healthtech and techbio startups leveraging data and computation.
• Industrial Biotech — Early-stage sustainable companies in agriculture, food, and materials sectors.

Investment thesis

Sofinnova Partners operates as a long-term life sciences investor with a mandate to improve patient outcomes through scientific innovation, backing companies from inception through IPO. The firm views patient impact and financial return as mutually reinforcing, stating that backing companies that bring products to patients ultimately translates into financial return.

• Therapeutic Focus — Invests in breakthrough biopharma and medtech innovations, with specific strategies for digital medicine, industrial biotech, and sustainable agriculture.
• Company Creation — Known as "company creators," utilizing in-house accelerators like Sofinnova MD Start and Biovelocita to build early-stage ventures from research organizations.
• Full-Value-Chain Coverage — Deploys capital across the entire lifecycle, from seed-stage therapeutic technologies to growth-stage commercialization via the Crossover Strategy.
• Strategic Partnerships — Prioritizes building lasting relationships with trust and transparency, acting as a partner for entrepreneurs navigating regulatory processes and company building.

Value add

Sofinnova Partners provides extensive operational support, leveraging its 50-year history and deep expertise in regulatory navigation and company building. The firm acts as a strategic partner, offering hands-on support through in-house accelerators and tailored strategic approaches.

Fit verdict: Ideal for life science founders seeking a long-term partner with deep operational expertise and a strong track record of guiding companies through regulatory hurdles and commercialization.

Founder diligence script:

• How does Sofinnova's in-house accelerator (MD Start/Biovelocita) integrate with its venture investing to support early-stage development?
• What specific regulatory and clinical development expertise does the firm bring to biopharma investments?
• How does the firm leverage its global network to facilitate partnerships and commercialization for medtech and digital medicine companies?
• What is the firm's approach to follow-on funding for portfolio companies across different strategies (Capital, Crossover, etc.)?
• How does Sofinnova measure and report on patient impact alongside financial returns?

Portfolio focus

• Biopharma & Therapeutics — Heavy concentration in drug development, including recent investments in Mironid (rare kidney disease) and HAYA Therapeutics (FDA Fast Track designation).
• Medtech & Surgical Tech — Significant presence in medical devices and surgical innovation, evidenced by collaborations with Moon Surgical and KARL STORZ.
• Digital Medicine & TechBio — Backing startups at the intersection of biology and computation, such as Mediar Therapeutics and partnerships with Genentech.
• Industrial & Sustainable Biotech — Investments in agriculture, chemicals, and materials sectors through the Industrial Biotech Strategy.

Notable investments & exits

• Mironid — Raised $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease [1].
• HAYA Therapeutics — Received FDA Fast Track Designation for HTX-001, indicating significant progress towards commercialization [1].
• Moon Surgical — Announced a strategic commercial collaboration with KARL STORZ to advance scalable surgery [1].
• MaxCyte — Announced a multi-platform technology license partnership with Genentech to advance cell therapy development [1].
• Mission Therapeutics — Struck a deal worth up to $292 million for Dimerix Ltd to develop an Acute Kidney Injury asset [1].

Strategic implications

Sofinnova's €4B AUM and 500+ portfolio companies signal a dominant position in European life sciences VC, with scale that allows it to back multiple strategies simultaneously. The firm's "company creator" model and in-house accelerators represent a structural advantage in sourcing and de-risking early-stage deals, particularly in medtech and industrial biotech. The firm's focus on patient impact as a driver of financial return aligns with the growing ESG and impact investing trends, potentially attracting LPs with dual mandates. The firm's global reach and European base position it to bridge the gap between European scientific innovation and global commercialization, particularly in the US market.

Where they could go further

The firm could deepen its focus on AI-driven drug discovery and digital health integration, given the rapid convergence of biology and data. Expanding its industrial biotech strategy to include more carbon capture and climate tech applications could align with broader sustainability trends and attract new LP capital. The firm could enhance its value proposition for founders by providing more structured support for international expansion, particularly in the US and Asia markets. Developing a more transparent reporting framework for patient impact metrics could strengthen the firm's brand as a purpose-driven investor and differentiate it from traditional VC firms.